Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-02	US$1.910	-3.54%	31,686
26-07-01	US$1.980	-4.81%	37,926
26-06-30	US$2.080	-5.45%	108,768
26-06-29	US$2.200	-8.33%	46,423
26-06-26	US$2.400	-4.76%	68,980

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:30:00 2026-07-02 EDT			5-day change	1st Jan Change
1.910 ^USD	-3.54%		-24.21%	-64.76%

06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	12.17M 10.64M 9.77M 9.11M 17.27M 1.16B 17.56M 118M 45.58M 568M 45.71M 44.72M 1.96B	P/E 2024	-2.88x	P/E 2025	-6.9x
Enterprise Value	8.6M 7.52M 6.9M 6.44M 12.21M 819M 12.41M 83.13M 32.22M 402M 32.31M 31.61M 1.38B	EV / Sales 2024	70.2x	EV / Sales 2025	-
Free-Float	64.62%	Yield 2024 *	-	Yield 2025	-

06-30	Exicure, Inc. Announces Board and Committee Changes, Effective June 30, 2026	CI
05-29	Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Exicure announces co-development agreement with Adbiotech for burixafor (GPC-100)	RE
04-22	Exicure, Inc. And Adbiotech Co., Ltd. Enter Co-Development Agreement For Burixafor (GPC-100)	CI
04-10	Exicure, Inc. Announces Management Changes	CI
03-27	Exicure, Inc. Announces Resignation of Director Sangjin Yeo from Board and Audit Committee, Effective March 27, 2026	CI
03-25	Exicure, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Exicure, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-17	Exicure appoints Jung Soo Kim as CEO and president	RE
02-17	Exicure, Inc. Announces Executive Appointments, Effective February 11, 2026	CI
02-17	Exicure, Inc. Appoints Gyuyeob Lee as Interim Chief Financial Officer, Effective February 11, 2026	CI
02-17	Exicure, Inc. Appoints Jung Soo Kim as Chief Executive Officer, Effective February 11, 2026	CI
02-10	Exicure, Inc. Announces Resignation of Seung Ik Baik as Chief Financial Officer, Effective February 9, 2026	CI

22-08-16	Chardan Adjusts Exicure's Price Target to $2 on 1-for-30 Reverse Stock Split, Maintains Neutral Rating	MT
22-03-29	Chardan Adjusts Exicure's Price Target to $0.25 From $0.40 'on Increased Dilution;' Neutral Rating Kept	MT
21-12-13	Chardan Downgrades Exicure to Neutral From Buy After Probe Shows Clinical Data Misrepresentation, Lowers PT to $0.40 From $2.25	MT
21-11-23	Chardan Adjusts Price Target on Exicure to $2.25 From $7 'on Uncertain Delays for Clinical Programs,' Keeps Buy Rating	MT
21-05-17	EXICURE : HC Wainwright Adjusts Price Target on Exicure to $6 From $8, Maintains Buy Rating	MT

Exicure, Inc. Stock

Stocks

XCUR

US30205M3097

Biotechnology & Medical Research

Valuation: Exicure, Inc.

Chart: Exicure, Inc.

Latest news : Exicure, Inc.

Analysts' recommendations: Exicure, Inc.

Press Releases: Exicure, Inc.

News in other languages: Exicure, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exicure, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

06-30	Exicure Announces Board and Committee Changes	AQ
06-10	Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement	AQ
06-01	Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q	AQ
04-22	Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)	AQ
04-02	Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions	AQ

21-08-02	Les valeurs à suivre aujourd'hui à Paris Lundi 2 août 2021
21-08-02	Ipsen : signe un partenariat avec Exicure dans les acides nucléiques sphériques
21-08-02	EN DIRECT DES MARCHES : Axa, Bolloré, Neoen, Ipsen, HSBC, Heineken, Square, Moderna...
21-08-02	Ipsen : accord de collaboration avec Exicure
21-08-02	Dernière ligne droite avant la coupure aoûtienne

1 day	-3.54%
1 week	-24.21%
Current month	-8.17%
1 month	-38.59%
3 months	-54.42%
6 months	-65.77%
Current year	-64.76%

1 week	1.77	2.5
1 month	1.71	3.2
Current year	1.71	6.64
1 year	1.71	9.5
3 years	1.44	36
5 years	1.44	297
10 years	1.44	975

Manager	Title	Age	Since
Jungsoo Kim CEO	Chief Executive Officer	-	2026-02-10
Gyuyeob Lee DFI	Director of Finance/CFO	40	2026-02-10
Josephine Cardarelli PSD	President	-	2025-10-05

Director	Title	Age	Since
Dong-Ho Lee BRD	Director/Board Member	64	2023-08-20
Jungsoo Kim BRD	Director/Board Member	-	2026-02-10
Gyeung Seog Cheon BRD	Director/Board Member	-	2026-02-08

Date	Insider	Type	Main position	Quantity	% Market Cap.
02-15	Josh Miller	Tax	Chief Accounting Officer	8	0.0001%
01-20	EXICURE HITRON, INC.	Sell	Company	258,367	4.0895%
01-15	EXICURE HITRON, INC.	Sell	Company	734,747	11.6298%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXICURE, INC.	-3.54%	-24.21%	-67.95%	-70.84%	12.62M
ARGENX SE	+3.98%	+5.55%	+76.40%	+132.19%	56.21B
WUXI APPTEC CO., LTD.	-3.12%	+5.11%	+71.57%	+94.67%	55.38B
BIONTECH SE	+3.86%	+8.38%	-9.90%	-9.62%	23.75B
INSMED INCORPORATED	+4.30%	+6.82%	+13.60%	+428.91%	23.19B
WUXI BIOLOGICS (CAYMAN) INC.	+3.64%	+10.54%	+39.81%	-4.50%	18.14B
GENMAB A/S	+4.11%	+9.85%	+42.56%	-27.36%	16.84B
PHARMAESSENTIA CORPORATION	+2.57%	+20.26%	+181.98%	+355.99%	15.86B
EXELIXIS, INC.	+3.50%	+4.92%	+26.07%	+192.26%	13.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+7.20%	+10.70%	+42.91%	-	12.97B
Average	+2.65%	+3.88%	+41.71%	+121.30%	23.59B
Weighted average by Cap.	+2.37%	+6.09%	+57.53%	+135.02%

	2024	2025
Net sales	500K 437K 401K 374K 709K 47.6M 721K 4.83M 1.87M 23.35M 1.88M 1.84M 80.45M	-
Net income	-9.7M -8.48M -7.78M -7.26M -13.76M -924M -13.99M -93.72M -36.32M -453M -36.43M -35.63M -1.56B	-4.95M -4.32M -3.97M -3.7M -7.02M -471M -7.13M -47.78M -18.52M -231M -18.57M -18.17M -796M
Net Debt	-6.46M -5.65M -5.19M -4.84M -9.17M -615M -9.32M -62.45M -24.2M -302M -24.27M -23.74M -1.04B	-3.57M -3.12M -2.86M -2.67M -5.06M -340M -5.15M -34.49M -13.37M -167M -13.4M -13.11M -574M